Physician profile
Wayne K Gabel
NPI 1144280488
$4,640.94
in general payments reported to CMS, 2019-2025
20 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2021: $518 · 2022: $729 · 2023: $661 · 2024: $630 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,082.47 | 2023-2025 | Miebo, Xiidra, Infuse |
| Coopervision INC. | $472.17 | 2023-2025 | Myday Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $363.62 | 2022-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $296.58 | 2019 | |
| Alcon Vision LLC | $282.48 | 2022-2025 | Dailies Total1, Precision7, Precision 1 |
| Rxsight INC | $257.92 | 2024-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Glaukos Corporation | $257.06 | 2021-2022 | |
| Shire North American Group INC | $246.87 | 2019 | |
| Kala Pharmaceuticals, INC. | $245.05 | 2021 | |
| Astellas Pharma US INC | $139.37 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $135.42 | 2019 | |
| Sight Sciences, INC. | $133.09 | 2022 | |
| Abbvie INC. | $132.71 | 2022 | |
| Mallinckrodt Hospital Products INC. | $125.00 | 2024 | Acthar |
| Horizon Therapeutics Plc | $124.13 | 2023 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $122.47 | 2021 | |
| Allergan, INC. | $90.12 | 2022 | |
| Visioneering Technologies, INC. | $69.60 | 2019 | |
| Biotissue Holdings INC. | $42.77 | 2024 | |
| Lkc Technologies, INC. | $22.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Gabel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.